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Abstract 
Heart Failure (HF) is an increasingly prevalent and costly multifactorial syndrome with high 
morbidity and mortality rates. The exact pathophysiological mechanisms leading to the 
development of HF are not completely understood. Several emerging paradigms implicate 
cardio-metabolic risk factors, inflammation, endothelial dysfunction, myocardial fibrosis, and 
myocyte dysfunction as key factors in the gradual progression from a healthy state to HF. 
Inflammation is now a recognized factor in disease progression in HF and a therapeutic 
target. Furthermore, the monocyte – platelet interaction has been highlighted as an important 
pathophysiological link between inflammation, thrombosis, endothelial activation, and 
myocardial malfunction. The contribution of monocytes and platelets to acute cardiovascular 
injury and acute HF is well established. However their role and interaction in the 
pathogenesis of chronic HF is not well understood. In particular, the crosstalk between 
monocytes and platelets in the peripheral circulation and in the vicinity of the vascular wall in 
the form of monocyte – platelet complexes may be a crucial element, which influences the 
pathophysiology and progression of chronic heart disease and HF. In this review, we discuss 
the role of monocytes and platelets as key mediators of cardiovascular inflammation in HF, 
the mechanisms of cell activation, and the importance of monocyte-platelet interaction and 
complexes in HF pathogenesis. Finally, we summarize recent information on 
pharmacological inhibition of inflammation and studies of anti-thrombotic strategies in the 
setting of HF that can inform opportunities for future work. We discuss recent data on 
monocyte – platelet interactions and the potential benefits of therapy directed at monocyte-
platelet complexes, particularly in the setting of HF with preserved ejection fraction. 
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Heart Failure and inflammation 
Cardiovascular disease is the number one cause of death in the world and chronic heart 
failure (HF) is an increasingly prevalent and costly multifactorial syndrome with high 
morbidity and mortality rates. HF affects approximately 1–3% of the population in developed 
countries and its prevalence rises to ≥10% in people over 65 years of age 1,2. There are 
predictions of an increase in HF prevalence by more than 40% by the year 2030 3 
predominantly due to ageing populations, increased population prevalence of cardio-
metabolic abnormalities and improved survival post myocardial infarction.  
HF is classified as either HF with preserved (HFPEF) or reduced (HFREF) ejection fraction 
and a cut-off of left ventricular ejection fraction (LVEF) above or below 50% is often used to 
differentiate these subtypes. The precise pathophysiological interactions, causes, and 
sequence of events leading to the development of HF have not been fully elucidated although 
HFREF is often associated with myocardial ischemia and infarction and is modifiable by 
several classes of pharmacologic and device therapy. HFPEF has a community prevalence at 
least as high as HFREF and is associated with older age, metabolic abnormalities and chronic 
hypertension leading to vascular and myocardial dysfunction 4.  
Several emerging pathophysiological paradigms implicate cardiometabolic risk factors, 
endothelial dysfunction (peripheral vascular, coronary vascular, and endocardial), 
inflammation, cardiomyocyte dysfunction, and myocardial fibrosis as key factors in the 
progression from healthy state to HF, including HFPEF 5-9. Such hypotheses suggest that in 
early stage HF cardiac injury is driven by systemic inflammation and assisted by heightened 
platelet activation and oxidative stress  arising from comorbid conditions such as 
hypertension, obesity, diabetes mellitus, iron deficiency, and chronic pulmonary and kidney 
disease 5-7,9-15. The heightened systemic inflammatory response affects the peripheral and 
heart vasculature and promotes endothelial inflammation (such as coronary microvascular 
endothelial inflammation 5, endocardial endothelial dysfunction 16), and oxidative stress.. 
This triggers a series of events including progressive invasion of pro-inflammatory cells 
through dysfunctional, “leaky” endothelium into the myocardium, disrupted endothelial nitric 
oxide (NO) bioavailability, further endothelial imbalances, phosphorylation deficits of major 
cardiomyocyte proteins such as titin, and increased cardiomyocyte stiffness. The aggravating 
imbalances promote myocardial dysfunction by altering the composition of the myocardial 
extracellular matrix, resulting in collagen deposition and imbalances in matrix 
metalloproteinases (MMP) and their tissue inhibitors (TIMP). In advanced HF myocardial 
damage occurs and is amplified by the concurrent exposure to imbalanced systemic, 
endothelial, and paracrine inflammatory mediators such as tumor necrosis factor alpha 
(TNFα), interleukins (IL) 1 and 6, C-reactive protein (CRP), monocyte chemotactic protein 1 
(MCP1), reactive oxygen species (ROS), NO, transforming growth factor beta (TGFβ) and 
MMP 5,17,18.  
Inflammation is a recognized factor in disease progression in both HFREF and HFPEF and a 
therapeutic target in this setting 19. However, initial clinical trials utilizing broad anti-
inflammatory therapies such as anti-TNFα agents in chronic HF patients (predominantly 
HFREF) have shown limited success (reviewed in Mann 2005 20 and Mann 2015 21). Indeed 
there is some evidence from post-hoc analyses of the anti-TNF therapy trial that those 
patients receiving higher dose therapy or longer duration of treatment had more adverse 
outcomes including heart failure and cardiovascular events 22. One solution proposed may be 
to focus again on the role of innate immunological responses in HF 21.  Another may be 
individualize therapy according to the etiology, severity and even subtype of HF (HFREF or 
HFPEF) due to the different nature of underlying causative and pathophysiological factors, 
associated comorbidities, and clinical presentation of the disease. For example, it is 
noteworthy that anti-inflammatory therapy using injections of modified autologous blood to 
non-specifically downregulate pro-inflammatory cytokines and increase production of anti-
inflammatory cytokines, showed benefits in patients with non-ischemic cardiomyopathy or 
patients with milder heart failure (NYHA class II) despite overall neutral results 23. A further 
approach might borrow from several large scale clinical trials which have been initiated in the 
setting of atherosclerosis, testing the effect of specific inhibitors of the IL1-TNFα-IL6 
pathway and related inflammatory pathways (oxidized-low density lipoprotein, P-selectin, 
phospholipase A2) that act to reduce inflammation in damage-sensitive systems such as the 
vessel wall, the monocyte/macrophage system, the adipose tissue, and the liver (reviewed in 
Ridker 2014 24). The results of these trials may advance the case for new, targeted anti-
inflammatory therapies for chronic cardiovascular diseases including HF. While, on one 
hand, a more effective therapeutic approach may benefit from targeting specific inflammatory 
mediators (such as monocytes) and/or specific inflammatory pathway(s) or components 
within this pathway(s) which have significant contribution to HF pathogenesis and 
progression, there has been limited success of targeted approaches to date. Undoubtedly 
further research is required to help define the relevant specific cellular partners and 
inflammatory pathways with the biggest potential impact for HF immunopathogenesis. 
Currently, anti-inflammatory therapy in HF patients is prescribed based on comorbidities and 
syndromes including atherosclerosis, acute coronary syndrome (ACS), previous MI, ischemic 
and non-ischemic CAD, myocardial ischemia, and atrial fibrillation. It involves, for example, 
the use of statins, anti-coagulants (aspirin, warfarin), corticosteroids, and non-steroidal anti-
inflammatory drugs (e.g. ibuprofen, naproxen) and while some studies have observed benefits 
associated with anti-inflammatory therapies to date, in many cases large scale studies of these 
therapies have resulted in neutral or even adverse effects in the failing heart 21,25,26. 
Alternatively, an approach for beneficially modulating inflammation in HF may be the use of 
combination therapy to target platelet activation, endothelial dysfunction and/or oxidative 
stress alongside inflammation and inflammatory cell activation. Benefits of restoring NO 
signalling (using, for example, endothelial NO synthase enhancers or NO donors) which 
modulate the pathway at the center of endothelial dysfunction, and of restoring endothelial 
function and normalizing platelet function have been shown to improve cardiac function in 
experimental animal models of cardiac stress, injury and HF(PEF) 27-30. A novel endothelial 
therapeutic approach with potential application in the HF setting utilized Protective 
Antioxidant Carriers for Endothelial Targeting (PACkET) to facilitate endothelial-targeted 
delivery of antioxidant enzymes (catalase and superoxide dismutase). This therapy provided 
vascular anti-oxidant and anti-inflammatory protection in animal models of inflammation and 
oxidative stress 31. In addition, inhibition of platelet activation was shown to prevent cardiac 
inflammation, fibrosis and adverse HF remodelling in response to angiotensin II insult in 
mouse models 32, and had beneficial effects (not confined to prevention of thromboembolic 
complications) on post chronic MI HF remodelling in rats with coronary ligation 33. 
Building on these promising non-clinical data, an approach targeting endothelial function, 
platelet activation, with or without anti-inflammatory therapy may improve HF treatment and 
prevention. Few studies have reported on this strategy in the clinic. In practice, similar to the 
situation with anti-inflammatory therapies in HF patients, pharmacological agents aimed at 
improving endothelial function and regulating platelet activity are only being used to treat 
patients with HF if they present with concomitant peripheral, cardiac or cerebral vascular 
disease, congestion, atrial fibrillation, or stroke. In this regard, retrospective observations 
about the beneficial impact of chronic, low dose antiplatelet therapy in HF have been made 34 
and disputed 35. Furthermore, among patients with reduced LVEF who were in sinus rhythm, 
there was no significant overall difference in outcome between treatment with warfarin and 
treatment with aspirin 36. Therefore, existing clinical studies on pharmacological inhibition of 
inflammation, leukocyte/monocyte, and platelet function and data examining the monocyte-
platelet interaction and its antagonism in HF are presented and discussed in this review. 
Overall, in the management of inflammation in HF there may be a need not only for further 
evaluation of novel pharmacological agents, but also novel therapeutic strategies which are 
able to regulate and target inflammatory cell-cell interactions and communication in the 
circulation. This may be of particular value in the coronary vasculature where endothelial 
dysfunction, inflammatory cell interactions and inflammatory mediator release from those 
cells (e.g. TNFα, IL6) may be critical to the development and progression of HF.  
Monocytes and platelets as mediators of cardiovascular inflammation in 
Heart Failure 
Platelets and monocytes are the principal cellular mediators of hemostasis in response to 
cardiovascular injury (reviewed in Rondina 2013 and Fernandez-Velasco 2014 37,38). 
Platelets, however, also play a major role in pathogenic thrombosis as a result of plaque 
rupture and endothelial dysfunction in atherothrombotic vascular diseases such as ACS,  
CAD, MI, cerebral ischaemia and cerebral ischaemic attack.  Platelets are mediators of 
inflammation and atherogenesis via interactions with leukocytes (monocytes, lymphocytes, 
neutrophils, basophils, and eosinophils) and the endothelium. A mechanistic role for platelets 
in the development of acute and chronic HF has been described 39,40. HF patients were shown 
to have higher mean platelet volume, increased whole blood aggregation, and higher levels of 
adhesion proteins including soluble and platelet-bound P-selectin and soluble CD40 ligand 
(sCD40L) 41-47.  Yet, despite the robust platelet activation and increase in activation markers, 
three studies in HF patients have shown that these may not modulate HF directly, but rather 
relate to future cardiovascular events via associated comorbidities 47-49. In the first study, 
Chung et al. reported increased levels of markers of platelet activation (soluble P-selectin, 
platelet surface P-selectin, and CD63) in stable congestive HFREF patients ( compared to 
healthy controls but not compared to CAD patients with normal LVEF > 50% 47. However, 
since none of the platelet markers in HF and CAD patients were predictive of future events, 
platelet abnormalities in HF were claimed to relate to associated comorbidities. A second 
study in ambulatory HFREF patients also showed heightened platelet activity unaffected by 
aspirin therapy compared to healthy controls 48. The degree of platelet activation was similar 
in ischemic and non-ischemic HF patients and was not related to disease severity or to 
outcome. Similarly, results from the congestive HF EPCOT trial which sought to assess the 
diagnostic utility of the platelet function analyzer (PFA-100) in HF, showed no significant 
differences when patients were divided by incidence of vascular events, emergency 
revascularization needs, survival, or HF etiology, suggesting that platelet abnormalities do 
not reliably predict clinical outcomes in this population 49. Furthermore, in three trials of 
aspirin versus warfarin in patients without concomitant anticoagulant or antiplatelet therapy 
and without a definite indication for antiplatelet therapy, there have been inconsistent results. 
The WASH and WATCH trials identified an increased risk of cardiovascular and HF events 
in aspirin users compared with warfarin users 50,51, whereas the WARCEF trial did not 
demonstrate a benefit of aspirin compared with warfarin use in this population 36. 
From a mechanistic viewpoint, a major role is anticipated for activated platelets in boosting 
systemic inflammatory responses, enhancing endothelial permeability and malfunction, and 
influencing subsequent tissue damage in cardiovascular disease and HF. These processes are 
regulated by platelet-induced activation of blood leukocytes and endothelial cells, enhanced 
platelet and leukocyte adhesion to endothelial cells, and enhanced leukocyte invasion into 
affected tissues. 
Leukocytes, particularly monocytes, play important roles in various cardiovascular (patho)-
physiological conditions including cardiovascular inflammation, wound healing, 
atherosclerosis, MI, ischemia, hypertension, and HF (reviewed in Swirski 2013 and Ghattas 
2014 52,53). The inflammatory phase of acute and chronic cardiac damage is characterized by 
inflamed myocardial tissue and endothelium of the adjacent coronary microvasculature. This 
results in chemo-attraction of monocytes, both of myeloid bone marrow 54 or splenic 55,56 
origin, via chemotactic signals (such as MCP1) secreted from susceptible endothelium and 
subsequent infiltration of these cells into the tissue. In the tissue, monocytes differentiate into 
macrophages with distinct phenotypic and functional properties dependent upon local 
cytokine stimuli. These macrophages release cytokines and mediators such as TNFα, MCP1, 
IL8, IL1, MMPs, and TGFβ which collectively contribute to the local inflammatory and 
fibrotic responses. Monocytes and macrophages are known to be major drivers of the 
inflammatory and fibrotic processes in cardiac disease and HF 57,58.  Increased activation of 
monocytes and abundant monocyte/macrophage infiltrates are seen in pressure-overloaded 
hearts in early and late stage HF and associate with exaggerated inflammation, tissue injury, 
fibrosis, but also tissue repair and revascularization 59-61 signifying a complex dual role of 
monocytes/macrophages in HF 57. 
Mechanisms of platelet and monocyte activation and interactions with the 
endothelium 
Platelet and endothelial activation 
As described above, the main function of platelets is hemostasis by formation of blood clots 
from activation of coagulation cascades as well as preservation of the endothelial balance and 
contribution to inflammation. Under physiological conditions NO derived from the L-
arginine pathway and cyclooxygenase (COX)-2-derived prostacyclin (PGI2) are secreted 
from intact endothelium to oppose platelet activation and adhesion 62. In malfunctioning, 
inflamed or disrupted endothelium, the release of inflammatory and stimulatory factors 
(adenosine diphosphate (ADP), Von Willebrand factor (VWF), tissue factor (TF), MCP1), 
the upregulation of adhesion molecules (E- and P-selectin, integrins (intercellular and 
vascular cell adhesion molecules (ICAM1 and VCAM1)), and the exposure and release of 
extracellular matrix proteins (collagen, fibrinogen, fibronectin) promote platelet shape 
change. This results in increased expression of pro-inflammatory and adhesion molecules (P-
selectin, sCD40L, platelet integrins: glycoprotein (GP) 1b, GP1b/V/IX. GPIIb/IIIa, GPVI), 
stimulating platelet activation, adherence and aggregation (reviewed in Jennings 2009, Davi 
2007, and van Gils 2009 63-65). Other signals promoting platelet activation include bacterial 
and viral infection, leukocyte activation, hematologic diseases affecting erythrocytes (e.g. 
anemia), immune and autoimmune disorders. In HF, circumstances that have the potential to 
promote platelet activation include hemodynamic changes and vascular factors, vascular 
endothelial dysfunction and reduced NO formation, renin-angiotensin system activation, 
increased catecholamine and cytokine release. These biochemical hallmarks are associated 
with co-morbidities including hypertension, iron deficiency, diabetes, ischemia, peripheral 
vascular disease, and valvular disorders 5,39,40. 
Activated platelets roll along the endothelium and attach to the site of injury via the platelet 
integrin receptors GP1b/V/IX, GPVI, and GP1b which recognize exposed VWF, collagen, 
and P-selectin on endothelial cells (reviewed in Varga-Szabo 2008 66). Firm adhesion to the 
endothelium is mediated via the subsequent formation of additional contacts between 
platelets, endothelial cells and secreted extracellular matrix proteins such as GPIIbIIIa – 
fibrinogen and GPVI / GP1a – collagen 66. Following initial adhesion, platelets respond to 
mediators that sustain and amplify the initial activation. The main amplifiers of platelet 
activation are the soluble agonists ADP, thromboxane A2 (TXA2), and thrombin. The actions 
of ADP and TXA2 are the targets of the most commonly prescribed antiplatelet drugs. Both 
ADP and TXA2 are released from adherent platelets to promote the activation, recruitment 
and accumulation of additional platelets. In physiological hemostasis and, mainly, in acute 
pathology this may lead to the formation of a growing thrombus. ADP interacts with the 
platelet receptor P2Y12 promoting platelet activation, an interaction antagonized by the P2Y12 
blockers clopidogrel, prasugrel, ticlopidine, ticagrelor, and cangrelor used for prevention of 
major vascular events in at-risk ACS and MI patients 67,68.  TXA2 is a transient metabolite of 
arachidonic acid produced by successive actions of prostaglandin- endoperoxide synthase-1 
(PTGS-1 or COX1) and thromboxane synthase 69. TXA2 exerts its effects by binding to its 
receptor expressed in various cells (platelets, endothelial cells, monocytes, macrophages, 
smooth muscle cells) and tissues (heart, kidney, spleen) 70. TXA2 is a key early stage platelet 
activating signal and its suppression provides the standard explanation for the cardio-
protective effects of low dose aspirin post-MI. Drugs that target the TXA2 pathways and their 
mechanisms of action have been reviewed by Fontana et al. 71.  These include not just the 
COX1 inhibitors (aspirin, triflusal) but also TXA2 synthase inhibitors (ozagrel, picotamide, 
ridogrel, EV-077) and TXA2 receptor antagonists (seratrodast, ramatroban, terutroban, 
picotamide, ridogrel, EV-077). Those have shown varying degrees of clinical efficacy in the 
treatment of peripheral artery disease, atherosclerosis, ACS, and asthma 72-76. Thrombin, 
known for cleaving fibrinogen to fibrin, is also a potent platelet activator that is rapidly 
produced at sites of vascular injury 77. It binds G-protein-coupled protease-activated receptors 
(PARs), mainly PAR1, on human platelets. Binding of thrombin to PAR1 leads to receptor 
cleavage and exposure of an active ligand. Anti-thrombin agents (bivalirudin, fondaparinaux,  
rivaroxaban, apixaban) and PAR1 inhibitors (vorapaxar, atopaxar) have been evaluated and 
have shown mixed effectiveness in clinical studies in patients with ACS, stable 
atherosclerotic disease, MI, stroke, and ischemia 68,78-85. As described above, in HF, anti-
platelet therapy is still indicated almost exclusively based on the presence of concomitant 
vascular disease. The use of anti-thrombotic therapy is also indicated in the setting of atrial 
fibrillation and data beyond this in HF are limited. Further discussion of clinical studies to 
date is provided below in the final section of this review (“Future perspectives on evaluation 
of drug therapy directed at monocyte-platelet interactions in HF”). 
Monocyte activation 
Monocytes and macrophages are essential components of the innate immune system with key 
functions in host defense to pathogens , inflammation, immune regulation, tissue 
remodelling, homeostasis, and metabolism (phagocytosis/removal of cell debris, iron 
recycling for reuse by the host, wound healing). Upon sensing of an activating signal, 
monocytes migrate through the endothelium into respective tissues and differentiate into 
macrophage effector cells and replenish long-lived resident tissue macrophages in the liver 
(Kupffer cells), spleen, peritoneum, central nervous system (microglial cells), bone 
(osteoclasts), and connective tissue (histiocytes) 86. There are different types of activating 
signals including infection components (bacterial LPS, lipopeptide, flagelin, and 
deoxyribonucleic acid (DNA); viral envelope glycoproteins; fungal zymosan and β-glycan), 
endogenous danger signals (cytokines: TNFα, IL1β, MCP1; soluble mediators: CD40 ligand, 
TXA2, platelet activating factors (PAF), leukotrienes, low-density lipoprotein, glucose), 
necrotic cells, and pathophysiological events (hypoxia, ischemia/reperfusion). These signals 
act on specific signal receptors on monocytes/macrophages which may or may not trigger an 
associated immune response. Homeostatic clearance of cells generated during tissue 
remodelling, clearance of apoptotic cells, and iron recycling from senescent erythrocytes is 
mediated by scavenger receptors, integrins, complement receptors, phosphatidyl serine 
receptors, and thrombospondin receptor (reviewed in Kono 2008 87). These regulatory 
processes do not generate an immune response or mediator release. Meanwhile, clearance of 
necrotic material containing endogenous activators like histones, DNA, heat-shock and 
nuclear proteins generated as a result of trauma and stress, as well as stress signals from 
chronic and acute inflammation and remodelling (ischemia/hypoxia, hypertension, cardiac 
stiffness/fibrosis, high cardiac filling pressures) are regulated by Toll-like receptors (TLR), 
the IL1 receptor, intracellular pattern recognition receptors, and chemokine receptors. In 
addition, bacteria and virus sensing activates pattern recognition receptors like TLR, 
cytoplasmic Nod-like receptors and retinoic acid inducible gene I-like helicase receptors, 
scavenger receptors (like CD163), the LPS receptor CD14, and C-lectins. This promotes 
pathogen elimination or neutralization by phagocytosis, antigen presentation, and cytokine 
release 87. These interactions induce an immune response with increased monocyte activation 
and monocytosis, which are characteristic for (auto)-immune and inflammatory diseases as 
well as for chronic inflammation associated with cardiovascular diseases 88,89. Ultimately, 
monocyte activation is reflected by a sequence of events including: 1) increased expression of 
monocyte surface proteins (MCP1 receptor CCR2, fractalkine receptor CX3CR1, P-selectin 
glycoprotein 1 (PSGL1), L-selectin, integrins, and CD40); 2) activation of intracellular 
inflammatory signalling cascades (nuclear factor kappa B (NFκB), intracellular response 
factors, signal transducer and activator of transcription); 3) release of pro-inflammatory 
cytokines (MCP1, TNFα, IL1β, IL8, IL6, TF) and ROS; 4) expression of remodelling and 
angiogenesis-associated mediators (MMP, TIMP, vascular endothelial growth factor); and 5) 
a change in monocyte shape and actin cytoskeleton rearrangements (Rho, Rac and Cdc42 
GTPases). Overall this results in monocyte mobilization and migration into tissue via 
increased MMP expression, upregulation of endothelial adhesion molecules (selectins, 
ICAM1, VCAM1), and NO synthesis.  
Mutual Platelet-Monocyte-Endothelial Cell activation  
A striking feature of monocyte/macrophage activation during cardiovascular stress or injury 
is the complex, dynamic communication network between circulating monocytes and 
activated platelets; circulating monocytes and activated endothelial cells; and platelets and 
endothelial cells, outlined in a recent review by van Gils et al. 65. The precise sequence of the 
events remains unclear and may indeed be heterogeneous, but the importance of this mutual 
platelet-monocyte-endothelial cell activation is established in cardiovascular pathophysiology 
90-93.  
Figure 1 presents the main events taking place within the platelet – monocyte – endothelial 
cell network. Under pathophysiological conditions, activated platelets adhere to the 
endothelium, secrete chemokines (MCP1, IL1β, chemokine C-C motif ligand 5 (CCL5), 
TXA2, TF, PAF, macrophage inflammatory protein), and increase expression of adhesion 
molecules (P-selectin, GP receptors, CD40L) to promote the recruitment of circulating 
monocytes. The latter roll, adhere (mainly via P-selectin/PSGL1, GP/integrin, and 
CD40L/CD40 interactions), and eventually migrate through the endothelium into adjacent 
tissues, facilitated by MMPs. In other circumstances, platelets may be activated while in the 
circulation, for example by cytokines released in systemic inflammation or thromboembolism 
(acute MI), by soluble agents released from platelets present at unstable thrombi 94, or as a 
result of turbulent flow.  These activated platelets bind preferentially to circulating 
monocytes in a P-selectin/PSGL1-mediated fashion and form monocyte-platelet complexes 
(MPCs) which show increased adhesive and migratory properties and aid the recruitment and 
activation of other, non-complexed monocytes 95. Some of the mechanisms involved include 
NFκB pathway activation, L-selectin shedding, increased integrin expression and activity, 
increased secretion of pro-inflammatory mediators and TF expression 96,97. MPCs are 
therefore regarded as functionally important inflammatory mediators.  
Briefly, in addition to the interactions between monocytes and platelets, platelet adhesion to 
the endothelium causes both platelet activation and endothelial activation. The interaction 
mediates the release of inflammatory chemokines (CCL5, platelet factor 4 (PF4), IL1β, 
macrophage migration inhibitory factor (MIF)) and mediators (TF, thrombin, PAF, ADP, 
TXA2), and upregulation of adhesion molecules (CD40L, P-selectin) from adherent platelets. 
In endothelial cells it activates NFκB and ROS production, upregulates endothelial adhesion 
molecules (VCAM1, ICAM1, E- and P-selectin), and regulates the secretion of different 
cytokines and mediators (MCP1, VWF, IL6, IL8, MMPs, granulocyte-macrophage colony 
stimulating factor) aimed at further monocyte and platelet activation, monocyte 
transmigration and macrophage differentiation 64,98.  
Another important aspect of monocyte/macrophage activation is the polarization of 
circulating monocytes to tissue macrophages of either the classical/M1 or the alternative/M2 
subset. This process is dependent on the type of monocyte activating signal and determines 
the phenotypic and functional traits of these cells and therefore the outcome of an immune-
inflammatory response. Classical/M1 macrophages are induced by pro-inflammatory 
mediators like interferon gamma (IFNγ), TNFα, and pathogen-associated TLR ligands (LPS). 
They express high levels of pro-inflammatory cytokines (IL1, TNFα, IFNγ, IL6, IL8, IL12, 
IL23), produce high levels of reactive nitrogen and oxygen intermediates, stimulate T-helper 
type 1 responses, have strong anti-microbial and anti-tumor activity, are involved in 
intracellular parasite killing, and mediate tissue destruction 99,100. M1 macrophage 
polarization regulates and is regulated by acute inflammation and infection, such as viral and 
bacterial infection, arthritis, atherosclerosis, diabetes (insulin resistance), and 
glomerulonephritis. Alternative/M2 macrophage activation is more complex due to the 
existence of several M2 subtypes. M2 macrophages can be induced by IL4, IL13; immune 
complexes, glucocorticoids, TLR and IL1 receptor ligands; or IL10, TGFβ, IL1β, and IL6 
and  are involved in parasite containment, T-helper type 2 responses, and tumor promotion. 
They are highly phagocytic, and express high levels of scavenger, mannose and galactose 
receptors 99,100. M2 polarization is mostly associated with chronic infection and inflammation, 
such as granuloma, helminths, cancers, renal and liver fibrosis, asthma, dermatitis, and 
wound healing (reviewed in Sica 2012 100). M2 are also involved in matrix deposition, tissue 
remodelling, angiogenesis, immune regulation, and immune suppression which is of 
importance in chronic fibro-inflammation observed in chronic HF. 
The importance of monocyte-platelet interactions and complexes in Heart 
Failure 
As described above, platelets and monocytes have been separately implicated in HF 
pathogenesis and pathophysiology 37,39,40,58.  
It is possible that a crucial, but insufficiently explored pathophysiological aspect of HF is the 
interaction between the endothelium, platelets, and monocytes in the setting of chronic, low 
grade inflammation arising from myocardial damage. A dysregulated, augmented cross talk 
between monocytes and platelets may be a critical factor influencing both the development 
and the progression of HF.  
The ability of activated platelets to interact with leukocytes, particularly monocytes, and form 
complexes in the peripheral circulation has been described long ago 101. MPC formation is 
increased in patients with autoimmune diseases such as rheumatoid arthritis, systemic lupus 
erythematosus, and antiphospholipid syndrome 102. MPCs are also increased and can be 
detected in the peripheral blood of patients with acute thrombotic disorders including acute 
MI 91,103,104, stroke 105-107, ACS 90,108, stable CAD 109, atherosclerosis 110,111, as well as in 
patients with atherothrombotic risk factors such as hypertension 112 and type I diabetes 113. 
The significance of MPCs in cardiovascular disease is further supported by the increased 
levels of MPCs found in the blood of patients following cardiovascular intervention 
(cardiopulmonary bypass) and by the positive correlation of MPCs with cardiovascular 
disease severity and prognosis 92,114,115.  
Since these conditions are both risk and etiological factors for HF, the importance of MPCs in 
HF development has also been recognized 46,116. Research in this area, however, is scarce and 
is challenged by the diverging etiologies and pathophysiology of the two types of HF, 
HFREF and HFPEF. While most research, including monocyte and platelet research, has 
traditionally been orientated to resolving interactions and disease mechanisms in the setting 
of ischemic heart disease and HFREF, accumulating new knowledge in HFPEF has 
highlighted the contribution of circulating factors, including leukocytes and platelets, to 
disease development and progression 5. Indeed evidence of monocyte and platelet activation 
separately has been shown in pre-HF and minimally-symptomatic phases of HFPEF 117. 
However, to date, mutual monocyte-platelet interaction/activation has not been investigated 
in HFPEF. 
While myocardial damage in HFREF was shown to be driven by oxidative stress to the 
myocardium originating from within the cardiomyocyte, in HFPEF the myriad of existing 
comorbidities and systemic and vascular inflammation (i.e. leukocyte and endothelial 
inflammation, platelet activation) are known to orchestrate cardiac remodeling and 
dysfunction 5,6. In this regard, the contribution of monocyte-platelet interactions and MPCs 
may also be important in the pathophysiology of HFPEF.  
Despite this, the few existing studies that have looked at MPCs in HF have examined only 
patients with HFREF. Increased MPC formation has recently been reported in ischemic HF in 
patients with acute as well as chronic stable HFREF (LVEF < 40%) 92. This was associated 
with increased MPC formation preferentially with pro-inflammatory monocyte subsets 
(CD14++CD16- and CD14++CD16+) in these HFREF patients compared with patients with 
stable CAD but no HF 92. Generally, the extent of MPC formation reflects the level of platelet 
activation and hyperactivity and is an index of blood thrombogenicity 103. More recently, 
platelet-monocyte interactions have emerged as an important pathophysiological link 
between thrombosis and inflammation, mainly due to platelet-induced inflammatory cytokine 
and prostanoid production from monocytes as well as increased monocyte endothelial 
adhesiveness 64,95-97,118,119. Those features highlight a likely regulatory role of monocyte-
platelet interactions and MPCs not only in acute cardiac ischemia, vascular disease and 
thrombosis but also in chronic non-ischemic HF 93. Indeed, abnormal platelet activity in 
chronic stable non-ischemic HFREF has been reported in one study, but these abnormalities 
were not predictive of outcome, notwithstanding the relatively small sample size 47. 
Furthermore, the authors concluded that platelet activation may simply be related to the 
comorbidities. Whether related to comorbidities or HF, it remains plausible that MPC 
formation contributes to the progression of fibro-inflammation and worsening of outcomes in 
HF, not only in HFREF, but also in HFPEF, which requires further evaluation.  
Areas for future research include the circulation time, clearance, and exact role of these 
complexes in vivo, in the setting of HF. Mechanistically, even though much is known about 
the triggers of MPC formation in the blood, the lack of data on MPCs in vivo hinders progress 
in defining the significance of MPCs in HF pathophysiology. The magnitude of MPC 
formation is primarily dependent on platelet activation and to some extent also on monocyte 
activation 95,120. The main protein interaction controlling platelet-monocyte binding at the 
vascular wall and in the circulation (MPC formation) is the one between P-selectin on 
activated platelets and PSGL1 on monocytes 95,121 (Figure 1). The crucial role of this 
interaction for MPC formation was verified by the use of P-selectin blocking antibodies 
which abrogated platelet adhesion to monocytes, whereas blocking other ligands had only 
minor effects 95,122. As described above, binding of monocytes to activated platelets to form 
MPCs induces expression of activating, pro-inflammatory cytokines and mediators from 
monocytes including IL1β, IL8, MCP1, and intracellular NFκB inflammatory signalling 
(Figure 1); and anti-P-selectin antibodies reduced cytokine production 118. In addition, an 
increase in high-sensitivity CRP, enhancement of pro-inflammatory monocytes subsets 
(CD14++CD16+), and increased monocyte adhesion to endothelial cells was reported as a 
result of increased platelet activation and MPC formation 119.  Those effects were reduced by 
the COX2 selective inhibitor NS-398, aspirin, and the -selective antagonist of prostaglandin E 
receptors 1 and 2, AH6809 119. Monocytes within MPCs show increased stable adhesiveness 
to activated endothelium due to increased expression and activity of β1 and β2 integrins and 
decreased expression of L-selectin which is involved in early monocyte rolling along the 
endothelium 96. These result in increased monocyte adhesion to ICAM1, VCAM1, and 
fibronectin and facilitate monocyte transendothelial migration. 
The circulation time and clearance of MPCs are not well defined and differ between humans 
and animals. In apolipoprotein-E-deficient mice, MPC formation was caused by injection of 
activated platelets. This was accompanied by increased CCL5, PF4, and increased VCAM1-
mediated monocyte binding to atherosclerotic endothelium. MPCs were found to be relatively 
short-lived (3-4 h) and cleared upon monocyte transmigration 121. Similarly, in primates MPC 
lifespan upon injection of thrombin-activated platelets was approximately 30 min while in 
patients with percutaneous coronary intervention, MPCs were detectable for up to 24 h 103. 
Similarly, acute MI patients registered higher levels of MPC formation with no increase in 
circulating P-selectin–expressing platelets. Of note, the lifespan of MPCs did not relate to P-
selectin shedding from platelet surface, which occurs several hours after MPC formation but 
may be related to increased adhesive capacity of these complexes 103.  A paper by van Gils et 
al. 123 has shed some light on the regulation of MPCs during transendothelial migration. The 
authors demonstrated in vivo that platelets localize to PSGL1 regions at the uropod of 
monocytes upon migration and detach from migrating monocytes and remain at the 
endothelial surface. MPC dissociation was associated with monocyte PSGL1 redistribution 
and mechanical stress, but not with reduced PSGL1 expression, reduced platelet-binding 
capacity of monocytes, or the type of endothelial matrix protein.  
Finally, the circulation time and clearance of MPCs might also depend on the extent of 
platelet phagocytosis mediated by activated monocytes, but this issue requires further study 
in the setting of HF. 
Future perspectives on evaluation of drug therapy directed at monocyte-
platelet interactions in HF 
Taken together, the available evidence shows heart failure is a hypercoagulable state 
independently of the presence of sinus rhythm and might support the hypothesis that 
monocyte-platelet-endothelial interactions and MPCs have an important role in HFREF as 
well as HFPEF pathogenesis and progression. Accepting this hypothesis would further point 
to putative clinical benefit of therapies directed at low-grade, chronic inflammation as well as 
platelet activation in the setting of HF. However, there are few conclusive clinical studies to 
support this hypothesis and, indeed, data from several large clinical trials have shown 
conflicting and even adverse outcomes with anti-thrombotic and anti-inflammatory therapy in 
HF (Table 1).  
In reconciling these observations several factors must be considered. Firstly, many of the 
studies to date have not been appropriately powered, prospective, randomized studies 
designed to address the hypothesis. Of the prospective, randomized studies, the HELAS 124 
and WASH 50 studies of anti-platelet/anti-coagulant strategies in HF were underpowered, as 
were anti-inflammatory studies of thalidomide, IV-IG therapy and IL-1 receptor antagonist 
anakinra in HF populations 125-127. In the larger WATCH study 51, which was terminated 
prematurely arising from recruitment difficulties, achieving 1587 of a planned 4500 
participants, there were no differences in the primary endpoint of death, non-fatal MI and 
non-fatal stroke between aspirin, warfarin and clopidogrel. However, this study raised a 
concern about excess hospitalizations for HF associated with aspirin versus warfarin and was 
in direct contrast to the subsequent WARCEF study 36, which was adequately powered, also 
showed no difference in primary endpoint between aspirin and warfarin, yet showed a trend 
to increased hospitalizations for HF in the warfarin versus aspirin treated patients. 
Secondly, almost all of the reported HF studies were carried out in HFREF patients, 
frequently with advanced disease, whereas there is some evidence from post-hoc analyses of 
the ACCLAIM study that anti-inflammatory therapies are likely to be most effective and 
beneficial in early stage HF 23. Furthermore, the possible benefit of anti-thrombotic therapy in 
HFPEF has yet to be formally tested in prospective, controlled studies. A small number of 
retrospective or observational studies have suggested that platelet activation is a feature of 
HFPEF and may be modifiable (Table 1) 34,127,128. There is only one small study of anti-
inflammatory therapy with IL-1 receptor antagonist anakinra in HFPEF 127 and one small 
prospective study of the same anti-inflammatory therapy in HFPEF currently recruiting 
(clinicaltrials.gov identifier NCT02173548). 
Thirdly, inappropriate dosing which can cause off-target or adverse effects and risks for the 
patient that eventually outweigh any clinical benefits may be an important reason for failure 
of anti-thrombotic/anti-inflammatory therapy in HF to date. For example, aspirin has proven 
anti-platelet effects at low doses (< 80 mg) commonly used in Europe and dose-related 
adverse effects at higher doses. Of particular concern in HF, modulation of vasodilating 
prostaglandins can occur at higher aspirin doses and it has been shown that there are dose-
dependent adverse renal effects of aspirin at doses > 80 mg daily 129. Despite this, in all of the 
prospective, randomized studies of aspirin in HF to date, higher daily doses were used. 
Similarly, it was shown in the ATTACH study that there is a significant increase in death and 
HF hospitalization with higher dose and longer treatment of the TNFα antagonist infliximab 
22. Given the chronic, low grade nature of inflammation in HF, doses and duration of anti-
inflammatory therapy should be considered in the study design. 
A forth consideration is that many of the trials include patients who may fall into the category 
of “indication for anti-thrombotic or anti-inflammatory therapy” independently of HF 
(including patients with ischemic heart disease, peripheral vascular disease, MI, 
atherosclerosis, stroke, atrial fibrillation), which makes evaluation of the benefits of anti-
thrombotic/anti-inflammatory drugs for HF very difficult. A related concern is the highly 
prevalent use of medications such as statins and aspirin among at-risk populations that 
persists long after the development of HF. However, as HF is a syndrome arising from other 
cardiovascular abnormalities, and involves multi-system pathology, the distinction between 
comorbidity and etiological factors is blurred and it may be unrealistic or even unwise to 
exclude patients with other conditions responsive to anti-thrombotic/anti-inflammatory 
therapy. 
Finally, more work is needed to expand our understanding of platelet–targeting agents 
beyond simple anti-coagulation/thrombotic agents, but also as means for regulation / 
modulation of other platelet functions, as well as leukocyte (monocyte) and endothelial 
function. The emerging importance of the platelet and endothelium in modulating tumor cell 
intravasation and extravasation 130 may have parallels with monocyte/macrophage 
intravasation in the myocardium as a key step in the pathogenesis of myocardial dysfunction 
in HF. Furthermore, it may be rational to use agents that interfere not with a single type of 
cell or event but with intercellular communication and actions. Therefore, there may be a role 
for modulating myocardial fibrosis using pharmacological agents that target monocyte as 
well as platelet function, the interaction of these cells in the circulation, MPC formation and 
the intravasation of monocyte-derived macrophages via inflamed vascular endothelium into 
the failing heart. 
This concept has been applied to atherosclerosis, where binding of platelet P-selectin to 
monocyte PSGL1 has been shown to promote activation of the interacting cells, release of 
pro-inflammatory mediators, endothelial adhesiveness and activation, monocyte 
transmigration into adjacent tissues, and thrombogenicity while its blockage had beneficial 
cardiovascular effects in the setting of atherosclerosis 110,120-123. While it is long recognized 
that the severity of interstitial fibrosis closely correlates with the extent of LV hypertrophy 
and impairment of ejection fraction 131,132, there is now a recognition of the potential 
importance of perivascular fibrosis in non-ischemic HF 133. In addition, suppressed NO 
production and responsiveness, increased P-selectin and circulating MPCs in hypertension, 
the main etiological factor associated with HFPEF 112, and increased serum soluble P-selectin 
in patients with diastolic dysfunction (independent of diabetes or CAD) 134 indicate a possible 
important contribution of the P-selectin – PSGL1 pathway in driving chronic HF, particularly 
HFPEF. Soluble, platelet-bound, and total P-selectin are also significantly increased in 
congestive HFREF (LVEF < 50%) 47. While the prognostic significance of this has yet to be 
determined it is interesting to note that a recent 10-year long-term follow-up study showed 
that soluble P-selectin has prognostic value in predicting cardiac events including cardiac 
death, non-fatal MI, and ACS with hospitalization in patients with preserved LVEF > 50% 
135. However, no study to date has evaluated the relationship between P-selectin levels and 
outcome in HF, nor explored the potential benefits of direct P-selectin – PSGL1 inhibition in 
therapy of chronic HF in patients. Interesting evidence from a transgenic mouse model of 
chronic HF with cardiac-specific overexpression of TNFα clearly showed that targeted 
disruption of P-selectin gene alongside ICAM-1 expressed by immune-inflammatory and 
endothelial cells improves cardiac function and survival 136. This may point to the benefit of 
modifying both platelet and monocyte activation in patients as outlined by Moertl et al. who 
showed that treatment with high dose (4 g/day) omega-3 polyunsaturated fatty acids reduced 
P-selectin, TF, and inflammatory cytokine release (IL6, TNFα) in patients with advanced 
non-ischemic, chronic HFREF 137. From a non-pharmacological perspective, exercise training 
(20 weeks) also significantly decreased soluble P-selectin and CD40 levels reflecting 
monocyte and platelet activation in patients with mild to moderate chronic HF 138.  
Other pharmacological agents aimed at inhibiting platelet or monocyte function, or both, with 
a potential to regulate monocyte-platelet interaction and MPC formation include anti-
thrombin agents, nitrates, PAR1 inhibitors, ADP antagonists, and TXA2 antagonists. The 
clinical benefits of these drugs in the context of wider, largely acute cardiovascular disease 
including peripheral artery disease, atherosclerosis, ACS, MI, and ischemia have been 
extensively. However, in the setting of HF, the evidence is scant. For example, a combination 
of aspirin (325 mg/day) and ADP P2Y12 blocker clopidogrel (75 mg/d) in advanced 
congestive HFREF (PLUTO-CHF trial) (LVEF < 40%, NYHA ≥ 2) resulted in significant 
inhibition of platelet activation (collagen-induced aggregation in plasma and whole blood) 
and expression of adhesion molecules (PECAM1, GPIb, GP IIb/IIIa antigen, GP IIb/IIIa, 
CD151) including P-selectin when compared with patients taking only aspirin 139. The 
combined therapy also reduced formation of platelet-leukocyte microparticles, an index of 
increased MPC formation 139. These effects were sustained in the broad spectrum of patients 
with HF independent of its etiology, severity (NYHA), or myocardial contractility 140. Similar 
effects on platelet function and platelet-leukocyte microparticles were also achieved by a 
combination of aspirin (325 mg/d) and selective serotonin reuptake inhibitors in congestive 
HFREF (LVEF < 40%, NYHA ≥ 2) 141. Similarly, treatment of stable, severe HFREF patients 
(NYHA III/IV) with the oral direct Factor Xa inhibitor rivaroxaban in a small study 
successfully reduced platelet activation and hypercoagulability, thus minimizing risk and 
improving clinical prognosis 142. Finally, in a study of 25 chronic HFREF patients awaiting 
transplantation, 11 received oral anti-thrombotic agents (target INR 2-3) associated with 
reduced fibrinolysis, inflammation, and endothelial dysfunction 143. These data once again 
suggest that important links exist between platelet, monocyte and endothelial cell function in 
HF and that it may be possible to modulate not only platelet function, but platelet-monocyte 
interactions using available pharmacological therapy. Furthermore, from the perspective of 
HF management, not only is evidence scant, but also almost exclusively in HFREF, rather 
than HFPEF patients. Although retrospective, observational data provide evidence of an 
association between antiplatelet therapy using COX1 inhibition with low dose aspirin (75 
mg/d) and improved HF outcomes in an unselected, mixed HFREF and HFPEF population 
(average LVEF: 40 ± 15%) 34 more prospective, randomized data are needed to explore the 
mechanisms and optimal pharmacological and non-pharmacological management of the 
adverse consequences of platelet-monocyte interactions in HF, particularly with preserved 
ejection fraction. 
Conclusion 
There are several emerging paradigms in the understanding of the pathophysiology of HF 
which implicate cardio-metabolic risk factors, inflammation, endothelial dysfunction, 
myocardial fibrosis, and myocyte dysfunction. The monocyte – platelet interaction has 
emerged in limited studies to date as a potentially important pathophysiological link between 
inflammation, thrombosis, endothelial activation, and myocardial dysfunction. This 
interaction may play a crucial role in promoting cardiac dysfunction by modulating 
thrombogenicity, inflammation, endothelial dysfunction, and oxidative stress and facilitating 
monocyte to macrophage infiltration in the myocardium promoting fibrosis and dysfunction.  
This may also be of particular importance in HFPEF, which has been under-investigated to 
date and is now acknowledged as a syndrome with a strong inflammatory component in pre- 
and minimally symptomatic phases, promoting a reactive cardiac fibrosis and dysfunction 5-
7,9. It is entirely plausible to draw the conclusion that inflammation is a correlate and not 
causative in HF from the clinical work to date in HFREF 21 and that therapies targeting the 
platelet are of little value in HF without established underlying indications. However, there 
may be lessons to learn in the design of future studies from the evidence base to date. 
Furthermore, the expanding knowledge in our understanding of immune modulation as well 
as molecular profiling to identify target patient subsets in a more personalized strategy offer 
hope. Finally, more studies in chronic HF, particularly HFPEF, are needed to properly assess 
the value of including therapeutic agents which target not only platelets and platelet 
activation, as current therapies do, but also monocytes 117, and more specifically platelet-
monocyte interactions. 
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Tables  
Table 1 Clinical trials in Heart Failure with Preserved and Reduced Ejection Fraction 
utilizing anti-platelet and anti-inflammatory therapies 
Ref. Study Type 
of HF 
Patients Therapy Study results 
Anti-platelet therapy 
124 HELAS; 
multicenter, 
randomized, 
double-
blind, 
placebo-
controlled 
trial; mean 
follow-up – 
19.5 +/- 1.6 
months 
(group-
dependent)  
HFREF 197 
HFREF 
patients 
with IHD 
or DCM 
IHD patients 
– aspirin (325 
mg/d) or 
warfarin (2.5-
10 mg/d, INR 
2-3).  
DCM 
patients – 
warfarin (2.5-
10 mg/d, INR 
2-3) or 
placebo 
No significant difference among 
the groups in the incidence of 
embolic events 
139 PLUTO-
CHF; 
prospective, 
randomized 
trial; mean 
HFREF 88 
outpatien
ts with 
congesti
Aspirin (325 
mg/d) and 
clopidogrel 
(75 mg/d) 
versus aspirin 
1) Combination therapy with 
aspirin and clopidogrel inhibits 
platelet activation and expression 
of adhesion molecules including 
follow-up – 
1 month 
ve 
HFREF 
(325 mg/d) 
alone 
P-selectin when compared with 
aspirin alone therapy 
50 WASH; 
open-label, 
randomized, 
controlled 
trial; mean 
follow-up – 
27+/- 1 
months 
HFREF 279 
patients 
with 
HFREF 
in sinus 
rhythm 
Aspirin (300 
mg/d) vs. 
warfarin 
(INR 2.5) vs. 
no therapy 
1) No difference in primary 
clinical outcome (death, nonfatal 
MI, or nonfatal stroke) between 
aspirin, warfarin or non-treated 
group 
2) Increased risk of all cause 
(re)hospitalization (secondary 
endpoint) in aspirin group 
51 WATCH; 
multination
al, 
prospective, 
randomized 
trial; mean 
follow-up – 
1.9 yrs. 
HFREF 1587 
patients 
with 
HFREF 
in sinus 
rhythm 
Double-blind 
aspirin (162 
mg/d) or 
clopidogrel 
(75 mg/d) vs. 
open-label 
warfarin 
(INR 2.5-3.0) 
1) All 3 drugs have equal 
beneficial effects with respect to 
primary end point (reduced all-
cause mortality, nonfatal MI, and 
nonfatal stroke) 
2) Warfarin is superior to aspirin 
and clopidogrel in reducing 
secondary endpoints (non-fatal 
stroke and (re)hospitalizations 
due to worsening HF), but 
associates with increased risk of 
minor bleeding 
36 WARCEF; 
double-
blind, 
HFREF 2305 
patients 
with 
Aspirin (325 
mg/d) vs. 
warfarin 
1) Similar beneficial effect with 
either drug on primary outcome 
multicenter 
trial; mean 
follow-up – 
3.5±1.8 yrs. 
HFREF 
in sinus 
rhythm 
(INR 2.0-3.5) (ischemic stroke, intracerebral 
hemorrhage, or all-cause death) 
2) No difference in primary 
outcome between treatment with 
warfarin or aspirin 
3) reduced risk of ischemic 
stroke with warfarin, offset by an 
increased risk of major 
hemorrhage 
4) a trend toward an increased 
rate of hospitalization for heart 
failure in the warfarin group, in 
direct contrast to the results of 
the WASH and WATCH trials 
34 Observation
al 
retrospectiv
e 
community-
based study; 
median 
follow-up – 
2.6 (0.8-4.5) 
yrs. 
HFREF 
and 
HFPEF 
1476 
patients 
with HF 
comorbi
dities 
attending 
a HF 
disease 
manage
ment 
program 
low-dose 
aspirin (75 
mg/d) vs. 
non-aspirin 
and high-
dose aspirin 
(>75 mg/d) 
1) low-dose aspirin associates 
with reduced mortality risk 
(primary endpoint) compared 
with non-aspirin use 
2) low-dose aspirin associates 
with reduced risk of HF 
hospitalization (secondary 
endpoint) compared with non-
aspirin use in the total population 
3) no difference in mortality or 
HF hospitalization between high-
dose aspirin users (>75 mg/d) 
and non-aspirin users 
Anti- inflammatory therapy 
128 Health 
ABC; 
observation
al 
community-
based study; 
median 
follow-up – 
9.4 yrs. 
HFPEF 
and 
HFREF 
2610 
(older) 
patients 
with HF 
comorbi
dities 
attending 
a HF 
disease 
manage
ment 
program 
Standard 
anti-
hypertensive, 
antithromboti
c, and anti-
inflammatory 
HF therapy 
1) Strong association of 
inflammatory markers (IL6, 
TNFα, CRP) with HF – 
particularly HFPEF – risk 
2) Monitoring of and intervention 
with inflammatory markers may 
improve risk stratification and 
reduce mortality in HFPEF  
144 RENEWAL 
(including 
RENAISSA
NCE and 
RECOVER)
; double-
blind, 
randomized, 
placebo-
controlled 
HFREF 1123 
patients 
(RENAI
SSANC
E) and 
925 
patients 
(RECOV
ER) with 
moderate 
Etanercept 
(25 mg/2x 
week) vs. 
etanercept 
(25 mg/3x 
week) vs. 
placebo 
(RENAISSA
NCE) 
 
1) The TNFα inhibitor etanercept 
had no effect on clinical status at 
24 weeks (primary endpoint) in 
RENAISSANCE or RECOVER 
2) Etarnecept had no effect on 
the death or chronic HF 
hospitalization end point in 
RENEWAL 
 
 
multicenter 
trial; mean 
follow-up – 
24 weeks 
to severe 
HFREF 
Etanercept 
(25 mg/ 
week) vs. 
etanercept 
(25 mg/2x 
week) vs. 
placebo 
(RECOVER) 
 
 
 
22 ATTACH; 
randomized, 
double-
blind, 
placebo-
controlled 
trial; mean 
follow-up – 
28 weeks 
HFREF 150 
patients 
with 
moderate 
to severe 
HFREF 
Infliximab (5 
mg/kg) vs. 
infliximab 
(10 mg/kg) 
vs. placebo at 
0, 2, and 6 
weeks after 
randomizatio
n 
1) Neither dose of the TNFα 
inhibitor infliximab improved 
clinical status at 14 weeks 
(primary endpoint) despite 
suppression of inflammatory 
markers and a modest increase in 
ejection fraction 
2) Significant increase in death 
and HF hospitalization at 28 
weeks in the patients who 
received 10 mg/kg infliximab  
23 ACCLAIM; 
double-
blind, 
placebo-
controlled 
randomized 
HFREF 2426 
patients 
with 
HFREF 
and HF 
hospitali
non-specific 
immunomod
ulation 
therapy 
(IMT) 
1) IMT was associated with a 
significant reduction in the risk 
of primary endpoint events 
(composite of time to death from 
any cause or first hospitalization 
for cardiovascular reason) 
trial; mean 
follow-up – 
10.2 months 
zation or 
iv drug 
therapy 
in an 
outpatien
t setting 
within 
the past 
12 
months 
vs. placebo 
by 
intragluteal 
injection on 
days 1, 2, 14, 
and every 28 
days 
thereafter 
2) Such benefits were seen also 
in patients without a history of 
MI (irrespective of NYHA) and 
patients within NYHAII. 
125 Double-
blind, 
placebo-
controlled 
randomized 
trial; mean 
follow-up – 
12 weeks 
HFREF 56 
patients 
with 
HFREF 
secondar
y to 
IDCM or 
CAD 
Thalidomide 
(25 mg QD 
increasing to 
200 mg QD) 
vs. placebo 
for 12 weeks 
1) The TNFα antagonist 
thalidomide significantly 
improved cardiac function 
(LVEF, in LV end-diastolic 
volume, heart rate) and improved 
matrix-stabilization by 
decreasing matrix 
metalloproteinase-2 (with no 
change in its inhibitor). These 
effects on LVEF were more 
marked in IDCM than in CAD 
2) Thalidomide had both pro- and 
anti-inflammatory effects (lower 
total neutrophil count, higher 
TNFα 
126 Double-
blind, 
placebo-
controlled 
randomized 
trial; mean 
follow-up – 
26 weeks 
HFREF 40 
patients 
with 
HFREF 
stratified 
accordin
g to 
cause 
(ICM 
and 
IDCM) 
Intravenous 
immunoglob
ulin (IVIG) 
vs. placebo 
for 26 weeks 
1) IVIG increased anti-
inflammatory mediators (IL10, 
IL1 receptor antagonist, soluble 
TNF receptors) and decreased N-
terminal pro-atrial natriuretic 
peptide favoring a net anti-
inflammatory effect in HFREF 
2) IVIG significantly improved 
LVEF, independent of the cause 
of HF  
127 D-HART; 
double-
blind, 
randomized, 
placebo-
controlled, 
crossover 
trial; mean 
follow-up – 
28 days 
HFPEF 12 
patients 
with 
HFPEF 
(LVEF ≥ 
50%) 
and 
evidence 
of 
systemic 
inflamm
ation 
Anakinra 
(100 mg) or 
placebo) for 
14 days and 
an additional 
14 days of 
the alternate 
treatment 
(placebo or 
anakinra) 
1) IL1 receptor blockade with 
anakinra significantly improved 
peak oxygen consumption 
(aerobic exercise capacity) and 
reduced plasma CRP (systemic 
inflammation) from baseline to 
the post-treatment follow-up 
point (primary endpoint). 
2) CRP reduction correlated with 
the improvement in peak oxygen 
consumption (secondary 
endpoint). 
INR, international normalized ratio; iv, intravenous; IDCM, idiopathic dilated 
cardiomyopathy; DCM, dilated cardiomyopathy; CAD, coronary artery disease; ICM, 
ischemic cardiomyopathy; IHD, ischemic heart disease   
Figure legends 
 
Figure 1 The monocyte – platelet – endothelial cell communication network. (1) 
Pathophysiological signals promote monocyte and platelet activation in the blood. Cell 
activation results in release of inflammatory mediators (IL1β, TNFα, IL6, IL8, MCP1, CRP, 
TF) and upregulation of adhesion molecules (P-sel, L-sel, CD40L, α/β-integrins, GP-R) in 
both monocytes and platelets, however with major contribution of monocytes. These aid 
monocyte – platelet interactions and formation of complexes (mainly in a P-selectin – 
PSGL1). Subsequent events include (2) platelet adhesion to the endothelium, (3) expression 
of adhesion (PSGL1, CD40, E-sel, ICAM1, VCAM1) and inflammatory (MMP, MCP1, 
VWF, IL6, IL8, TF, thrombin) mediators from activated endothelium, and (4) recruitment, 
adhesion and transmigration of monocytes across the endothelium. The precise order of the 
latter three events is unclear as they may happen simultaneously and each one may precede 
another of happen as a result of it. In either case, (5) endothelium-adherent platelets secrete 
an array of inflammatory chemokines and mediators (ADP, TXA2, PAF, TF, thrombin, 
MCP1, IL1β, MIF, CCL5) aimed at recruitment and adhesion of more platelets (in 
physiological and pathological thrombus formation) and recruitment and activation of 
monocytes, which (6) back-loops to further boost monocyte – platelet interactions. 
 
